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Abstract: 34	  
There is considerable preclinical and clinical evidence indicating that abnormal changes in 35	  
glutamatergic signaling underlie the development of mood disorders. Astrocytic glutamate 36	  
dysfunction, in particular, has been recently linked with the pathogenesis and treatment of 37	  
mood disorders, including anxiety and depression. System xc- is a glial cystine/glutamate 38	  
antiporter that is responsible for nonvesicular glutamate release in various regions of the 39	  
brain. Although system xc- is involved in glutamate signal transduction, its possible role 40	  
mediating anxiety or depressive-like behaviors is currently unknown. In the present study, we 41	  
phenotyped adult and aged system xc- deficient mice in a battery of tests for anxiety and 42	  
depressive-like behavior (open field, light/dark test, elevated plus maze, novelty suppressed 43	  
feeding, forced swim test, tail suspension test). Concomitantly, we evaluated the sensorimotor 44	  
function of system xc- deficient mice, using motor and sensorimotor based tests (rotarod, 45	  
adhesive removal test, nest building test). Finally, due to the presence and potential functional 46	  
relevance of system xc- in the eye, we investigated the visual acuity of system xc- deficient 47	  
mice (optomotor test). Our results indicate that loss of system xc- does not affect motor or 48	  
sensorimotor function, in either adult or aged mice, in any of the paradigms investigated. 49	  
Similarly, loss of system xc- does not affect basic visual acuity, in either adult or aged mice. 50	  
On the other hand, in the open field and light/dark tests, and forced swim and tail suspension 51	  
tests respectively, we could observe significant anxiolytic and antidepressive-like effects in 52	  
system xc- deficient mice that in certain cases (light/dark, forced swim) were age-dependent. 53	  
These findings indicate that, under physiological conditions, nonvesicular glutamate release 54	  
via system xc- mediates aspects of higher brain function related to anxiety and depression, but 55	  
does not influence sensorimotor function or spatial vision. As such, modulation of system xc- 56	  
might constitute the basis of innovative interventions in mood disorders.  57	  
 58	  
Keywords:  59	  
system xc-, xCT, anxiety, depression, sensorimotor, vision 60	  
 61	  
Abbreviations:  62	  
NMDA, N-Methyl-D-Aspartate; xCT-/-, xCT knock-out mice; xCT+/+, xCT wild-type mice 63	  
 64	  
 65	  
 66	  
 67	  
3 
 
1. Introduction 68	  
Depression and anxiety are among the most prevalent mood disorders in our current society. 69	  
Therapeutic management of these psychiatric disorders relies on classical approaches 70	  
targeting the monoaminergic neurotransmission systems, which although they have proven 71	  
their usefulness, are limited in terms of efficacy and side-effects profile (Li et al., 2012). Lack 72	  
of innovative therapies for anxiety and depression is related to an incomplete understanding of 73	  
the pathophysiological basis of these complex disorders and the limited knowledge about the 74	  
cellular downstream adaptations causing the slow onset of the current monoaminergic drugs 75	  
(Li et al., 2012;  Sanacora et al., 2008). Glutamate, the major excitatory neurotransmitter in 76	  
the brain, has been implicated in the manifestation of stress and mood disorders (Popoli et al., 77	  
2012). The finding of altered glutamate levels in plasma and cerebrospinal fluid, as well as 78	  
changes in glutamate content in brain tissue of patients with mood disorders, indicates a 79	  
possible pathogenic contribution (Li et al., 2012;  Sanacora et al., 2008). Clinical proof-of-80	  
concept studies show rapid antidepressant activity of N-Methyl-D-Aspartate (NMDA) 81	  
receptor antagonists, such as ketamine, in patients with major depressive disorder (Li et al., 82	  
2012;  Zarate et al., 2010). Alterations in astrocytic glutamate regulation, including 83	  
perturbation in glutamate reuptake mechanisms and glutamate metabolism have been linked 84	  
with depression (Gomez-Galan et al., 2013;  Popoli et al., 2012). Finally, increasing evidence 85	  
points to the involvement of glial cell pathology in disease processes associated with mood 86	  
and anxiety disorders (Sanacora and Banasr, 2013;  Sanacora et al., 2008). 87	  
 88	  
System xc- is a glial plasma membrane antiporter that imports cystine and exports glutamate 89	  
to the extracellular environment in a 1:1 ratio (Lewerenz et al., 2013). Structurally, system xc- 90	  
is a heterodimer composed of 4F2hc and xCT, with xCT being the specific subunit and 91	  
mediating the transport function of the antiporter (Lewerenz et al., 2013). We have previously 92	  
demonstrated that in regions of the brain such as the striatum (Massie et al., 2011) or 93	  
hippocampus (De Bundel et al., 2011), nonvesicular glutamate release by system xc- is the 94	  
major source of extracellular glutamate, which in turn might mediate tonic activation of 95	  
extrasynaptic glutamate receptors, including group I and group II metabotropic glutamate 96	  
receptors as well as extrasynaptic NMDA receptors (Bridges et al., 2012). Via these 97	  
pathways, system xc- is thought to play a modulatory role on the glutamatergic signaling in 98	  
the brain. Nevertheless, the possible effect of system xc- on emotional features of behavior, 99	  
such as those related to anxiety or depressive-like behavior, is currently unknown. These gaps 100	  
in our understanding of the functional relevance of system xc- in the brain are also a result of 101	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lack of selective pharmacological modulators (Lewerenz et al., 2013), consequently genetic 102	  
approaches offer an alternative way to dissect the contribution of specific proteins to behavior 103	  
(Cryan and Holmes, 2005). We have previously indicated that mice lacking xCT (xCT-/-) 104	  
(Sato et al., 2005) do not demonstrate severe motor dysfunction, have an intact spatial 105	  
reference memory, but demonstrate an impaired spatial working memory (in adult but not 106	  
aged mice), potentially due to the decreased extracellular glutamate levels in the hippocampus 107	  
(De Bundel et al., 2011). In the current study, we extend our behavioral characterization of 108	  
system xc- deficient mice, with particular focus on anxiety and depressive-like behavior. 109	  
Furthermore, as system xc- is potentially expressed in areas of the brain regulating 110	  
sensorimotor function, such as the basal ganglia (Baker et al., 2002;  Massie et al., 2011) and 111	  
cerebellum (Sato et al., 2002;  Shih et al., 2006), we evaluated differences in sensorimotor 112	  
function in xCT-/- mice compared to xCT+/+ littermates. For both affective and sensorimotor 113	  
function, we employed a battery of behavioral tests to reduce false negative results and 114	  
evaluate specific aspects of behavior (Crawley, 2008). Finally, due to the presence and 115	  
potential functional relevance of system xc- in the eye (Bridges et al., 2001;  Langford et al., 116	  
2010;  Lim et al., 2005), we investigated whether loss of xCT would lead to impairment in 117	  
visual acuity. We included in our phenotypic screen both adult (16-20 weeks old) as well as 118	  
aged (19-23 months old) mice, in order to evaluate whether changes in behavior would be 119	  
consistently observed across aging, as well as to investigate whether loss of system xc- affects 120	  
the aging process in terms of behavior.  121	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2. Materials and Methods 136	  
 137	  
2.1. Animals 138	  
This phenotyping study was performed on adult (16-20 weeks old) and aged (19-23 months 139	  
old) male xCT-/- mice and xCT+/+ littermates. The mice used in this study are high-140	  
generation descendants of the strain described previously (Sato et al., 2005), and were bred in 141	  
the animal facilities of the Vrije Universiteit Brussel. The xCT null mutants were generated 142	  
by targeted disruption of the START codon in exon 1 of the Slc7a11 gene, and were 143	  
backcrossed for more than 12 generations on a C57BL/6J background. Mice were group-144	  
housed (2-6 mice per cage) under standardized conditions (25oC, 10/14 h dark/light cycle), 145	  
with free access to food and water. Studies were performed according to national guidelines 146	  
on animal experimentation and were approved by the Ethical Committee for Animal 147	  
Experimentation of the Faculty of Medicine and Pharmacy of the Vrije Universiteit Brussel.  148	  
 149	  
2.2. Genotyping 150	  
Genotypes were confirmed by PCR amplification of tail DNA using REDExtract-N-Amp 151	  
Tissue PCR Kit (Sigma), and the following primers: 5′-GATGCCCTTC 152	  
AGCTCGATGCGGTTCACCAG-3′ (GFPR3); 5′-CAGAGCAGCCCTAAGGCACTTTCC-3′ 153	  
[mxCT5′flankF6]; 5′-CCGATGACGCTGCCGATGATGATGG-3′ [mxCT(Dr4)R8]. 154	  
 155	  
2.3. Phenotyping 156	  
In this retrospective study, behavioral phenotyping was performed at various time points 157	  
during a two-year period, using seven different breeding batches of naive mice (no 158	  
experimental history prior to behavioral assessment) matched by genotype and age. Tests 159	  
were performed sequentially during a period of one month (starting from the least stressful 160	  
test, e.g. open field test, to the more stressful, e.g. tail suspension test), with each test 161	  
performed on a different day. The age of the mice at the beginning of the tests was 16-20 162	  
weeks old (for adult mice) or 19-23 months old (for aged mice). Not all mice included in this 163	  
study were tested in all of the paradigms described. The initial batches of mice were tested for 164	  
spontaneous activity (open field test), while subsequent batches also included specific tests 165	  
evaluating sensorimotor function, vision, anxiety- or depressive-like behavior. Behavioral 166	  
assessment was performed between 9:00 AM and 6:00 PM (during the light phase), with 167	  
alternate testing of xCT-/- and xCT+/+ mice to ensure evaluation of both genotypes during the 168	  
same time of the day. For tests requiring real-time behavioral scoring (nest building test, 169	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adhesive removal test, optomotor test, novelty-suppressed feeding test), blinding for genotype 170	  
was ensured by the presence of an additional researcher blinded to test order during the 171	  
experiment. For tests integrated off-line (light/dark test, elevated plus maze test, forced swim 172	  
test, tail suspension test), blinding for genotype was ensured by integrating the acquired video 173	  
files in a blinded manner. For the remaining tests (rotarod, and open field tests), blinding for 174	  
genotype was ensured by employing objective and automated integration systems (TSE 175	  
RotarRod Systems, and Noldus Ethovision respectively). For each test, mice were 176	  
acclimatized to the testing room at least 1 hour prior to assessment.  177	  
 178	  
2.3.1. Open field test 179	  
The open field set-up consisted of a square box (60 cm x 60 cm) with surrounding walls 180	  
(height 60 cm) that prevent escape, manufactured in clear poly(methyl-methacrylate) 181	  
(Plexiglas), with black opaque walls that prevent observation of visual cues outside the arena. 182	  
The center of the arena was defined as the central 40 cm x 40 cm zone. The light levels in the 183	  
room created an illuminance of 150 lux at the center of the open field. Total distance traveled 184	  
and frequency of rearing (as measures of exploratory behavior), as well as time spent in the 185	  
center zone (as measure of anxiety-like behavior), were calculated. The experiment was 186	  
recorded by a video tracking system (Ethovision software, Noldus, The Netherlands) for 60 187	  
minutes. 188	  
 189	  
2.3.2. Rotarod test 190	  
Motor functions were investigated using an accelerating rotarod system (TSE RotaRod 191	  
Advanced, TSE Systems). First, mice were trained for 5 minutes at a constant speed of 5 rpm. 192	  
During this initial training phase, mice were placed immediately back on the rod after falling, 193	  
allowing them to get familiarized to the test. In the second phase of training, mice underwent 194	  
3 repeated trials of 1 minute at a fixed speed of 5 rpm, with 3 minutes of rest between trials. 195	  
For the test, mice underwent 5 repeated trials that started at constant speed of 5 rpm for 30 196	  
seconds, and continued with a 5 rpm – 25 rpm accelerating protocol during 200 seconds, 197	  
leading to a maximum total rod time of 230 seconds. Mice were allowed 3 minutes of rest 198	  
between trials. We applied statistical analysis on the mean of the 5 test trials. 199	  
 200	  
2.3.3. Nest building test 201	  
Sensorimotor performance and skilled forelimb use were investigated using the nest building 202	  
test, as described previously (Deacon, 2006). In this paradigm, mice were individually housed 203	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overnight in a non-enriched cage, and challenged to build a nest starting from nesting material 204	  
in order to provide shelter and heat insulation. The following morning, the quality of the nest 205	  
was scored on a 0-5 scale, with 0 representing no nest, and 5 a perfect nest (Deacon, 2006). 206	  
Furthermore, in order to provide a semi-independent objective assay of nesting ability, the 207	  
amount of nesting material shredded was quantified, by weighing the complete nesting 208	  
material (one pressed cotton Nestlet™ square) before the test, and weighing the untorn 209	  
material at the end of the test. 210	  
 211	  
2.3.4. Adhesive removal test 212	  
Sensorimotor performance was assessed using the adhesive removal test, as described 213	  
previously (Bouet et al., 2009). After mice were habituated to a transparent test box for 60 214	  
seconds, small adhesive strips (0.3 cm x 0.4 cm) were taped on the plantar surface of both 215	  
forelimbs, by applying equal pressure. Next, the mice were placed back in the test box. Two 216	  
parameters were counted: time-to-contact, defined as the time required for the mouse to sense 217	  
the presence of the adhesive (i.e. mouth to paw contact) and being indicative of correct paw 218	  
and mouth sensitivity; and time-to-remove, defined as the time required to completely remove 219	  
the adhesive from the paw, reflecting sensorimotor performance (Bouet et al., 2009). If the 220	  
mouse did not feel or remove an adhesive during the trial, a maximum time of 120 seconds 221	  
was given. The shortest time-to-contact and time-to-remove from the two forepaws underwent 222	  
statistical analyses. Initially, mice were trained for 5 days by performing the test in identical 223	  
conditions as the test condition. The adhesive placement order (left forepaw or right forepaw 224	  
first) was alternated for each day of training during the first 4 days, and randomized for the 225	  
last day of training, and for the test session. 226	  
 227	  
2.3.5. Virtual-reality optomotor system 228	  
Visual acuity of mice was estimated using the detection of optokinetic head movements in the 229	  
virtual-reality optomotor system developed by Prusky et al. (Prusky et al., 2004). Briefly, the 230	  
testing apparatus (OptoMotry, CerebralMechanics) consisted of a box made of four computer 231	  
screens (Four 20-inch LCD monitors) onto which a virtual cylinder comprised of a vertical 232	  
sine wave grating was projected and a platform was situated at the epicenter of the arena. A 233	  
video camera was secured to the top lid of the box, directly above the platform to observe the 234	  
behavior of untrained and freely moving animals. Individual mice were exposed to moving 235	  
sine wave gratings of different spatial frequencies at 100% contrast and at a fixed speed (12 236	  
degrees per second). The experimenter judged the presence of head movements in concert 237	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with the cylinder rotation that represent their slow reflexive tracking of the gratings and a 238	  
feeling of self-motion (Douglas et al., 2005). Marking the location between the eyes of the 239	  
mouse with a crosshair provided positional information to the software to center the rotation 240	  
of the cylinder at the mouse’s viewing position, thereby maintaining the virtual walls of the 241	  
cylinder at a constant distance from the mouse. Visual thresholds for spatial vision were 242	  
obtained with a staircase procedure and drum rotation was random from trial to trial. By 243	  
varying the spatial frequencies randomly and separate for each eye, the ability of the mouse 244	  
visual system to detect the visual stimuli was determined and the highest spatial frequency 245	  
capable of driving a response was adopted as the threshold. 246	  
 247	  
2.3.6. Light/dark paradigm  248	  
The light/dark paradigm investigates the spontaneous exploratory behavior of rodents in 249	  
response to mild stress, in this case being a novel and well-illuminated environment. The test 250	  
apparatus consisted of an open field arena (60 cm x 60 cm; height 60 cm) manufactured in 251	  
clear Plexiglas, with black opaque walls that prevent observation of visual cues outside the 252	  
arena. A small dark compartment (one fourth of the total area), manufactured in black high-253	  
pressure laminate (Volkern-Trespa), was positioned in one of the corners of the open field 254	  
arena. The light/dark test was performed in a dark room in which the open field arena was 255	  
illuminated with three overhead lamps, creating a light contrast (illuminance outside the 256	  
shelter 700 lux, inside the shelter 0.5 lux). In this conflict test, anxious behavior is 257	  
investigated by comparing the innate exploratory activity of the mice with the preference for 258	  
an enclosed, safe shelter. Mice demonstrate an aversion to brightly illuminated areas, and 259	  
therefore prefer to stay in the small dark compartment during the trial. The test takes 5 260	  
minutes in total and mice were placed in the dark zone at the start. The trial was videotaped 261	  
and timed manually by a blinded researcher. Anxiolytic behavior is characterized as the time 262	  
the subject spends outside the shelter and the latency time before the first exit (Pogorelov et 263	  
al., 2007). 264	  
 265	  
2.3.7. Novelty-suppressed feeding test 266	  
The novelty suppressed feeding test is a conflict test that evokes competing motivations: the 267	  
drive to eat versus the fear to enter the center of a brightly lit box. In this way hyponeophagia 268	  
can be considered a parameter for both depressive- and anxiety-like behavior. The procedure 269	  
was slightly adapted from Mineur et al. (Mineur et al., 2007). For this test, mice were 270	  
deprived from food for 24 hours before the start of the experiment, water remained available 271	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ad libitum. Each subject was placed in a corner of an open Plexiglas box (60 cm x 60 cm; 272	  
height 60 cm) with a one cm layer of bedding and one food pellet in the center. The 273	  
illuminance in the center of the open field arena was 150 lux. The time to the first feeding 274	  
episode was recorded by a researcher blinded to the genotype. 275	  
 276	  
2.3.8. Elevated plus maze 277	  
The elevated plus maze protocol is based on the aversive nature of mice for an open, elevated, 278	  
unprotected area. We used a cross-shaped maze manufactured in black high-pressure laminate 279	  
(Volkern-Trespa), and elevated to a height of 37 cm from the ground. The elevated plus maze 280	  
consisted of two arms without walls and two enclosed by walls (32.5 cm length x 6 cm width 281	  
x 17 cm height), with a center area of 6 cm x 6 cm (Rodgers et al., 1995). The illuminance at 282	  
the level of the open arms was 150 lux. Mice were placed at the junction of the maze, facing a 283	  
closed arm and allowed to explore the maze for 10 minutes. Each mouse was video-recorded 284	  
during the test, and the researcher left the room after the start of the trial. Time spent in the 285	  
open arms and the number of open arm entries are parameters for anxiolytic behavior. The 286	  
duration and entries in the open and closed arms were timed manually by a blinded 287	  
researcher. 288	  
 289	  
2.3.9. Forced swim test 290	  
A modified version of the forced swim test, originally described by Porsolt et al., was used to 291	  
assess depressive-like behavior (Porsolt et al., 1977). Mice were placed in a glass tank 292	  
cylinder filled with 30 cm of water (25 ± 1 °C) and videotaped during 5 minutes. The 293	  
inescapability of the set-up induces a state of helplessness. The light levels in the room 294	  
created an illuminance of 400 lux at the level of the forced swim test. Cryan et al. described a 295	  
time sampling technique, whereby the predominant behavior in each 5 second period of the 296	  
300 seconds test was recorded by a blinded researcher (Cryan et al., 2002). Three types of 297	  
behavior were distinguished: climbing behavior consisted of upward-directed movements of 298	  
the forepaws along the side of the swim tank (also called thrashing). Swimming behavior was 299	  
defined as mostly horizontal movement across the swim tank. Immobility was assigned when 300	  
no additional activity was observed other than that required to keep the mouse’s head above 301	  
the water surface (Cryan et al., 2002). As the trial time was 300 seconds, a total number of 60 302	  
counts per mouse were recorded, which were divided between climbing, swimming, and 303	  
immobility. 304	  
 305
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2.3.10. Tail suspension test 306	  
Besides the forced swim test, the tail suspension test is one of the most widely used tests for 307	  
the examination of depressive-like behavior in mice. The set-up was similar to that described 308	  
by Steru et al. (Steru et al., 1985). Mice were suspended by the tip of their tail for 5 minutes to 309	  
induce an inescapable, short-term stress situation. The light levels in the room created an 310	  
illuminance of 400 lux at the level of the tail suspension test. The time of immobility was 311	  
measured by a blinded researcher and is considered a parameter for depressive-like behavior. 312	  
Mice that climbed their tail were excluded from the experiment. 313	  
 314	  
2.4. Statistical analysis 315	  
Data are expressed as mean ± standard error of the mean (SEM). Statistical analyses were 316	  
performed using GraphPad Prism 4.0 software. For all analyses, we employed a two-way 317	  
ANOVA followed by Bonferroni post hoc tests. The α value was set at 0.05. 318	  
 319	  
 320	  
 321	  
 322	  
 323	  
 324	  
 325	  
 326	  
 327	  
 328	  
 329	  
 330	  
 331	  
 332	  
 333	  
 334	  
 335	  
 336	  
 337	  
 338	  
 339	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3. Results 340	  
 341	  
3.1. Effect of xCT deletion on motor and sensorimotor function 342	  
The spontaneous horizontal and vertical motor activity of the xCT-/- and xCT+/+ mice was 343	  
measured in a 60 minute open field test. Distance traveled, as measure of horizontal activity 344	  
(see Fig. 1A for 5 minute time bins), was unaffected by the loss of xCT, as xCT-/- mice 345	  
demonstrated similar activity levels compared to their xCT+/+ littermates irrespective of age, 346	  
for either the first 5 minutes of the test [genotype factor: F(1,128)=3.796, p=0.053; Fig. 1B], 347	  
or the entire 60 minute trial [genotype factor: F(1,128)=0.460, p=0.499; Fig. 1C]. Total 348	  
distance traveled decreased with aging independent of genotype during the first 5 minutes of 349	  
the test [age factor: F(1,128)=62.96, p<0.0001], but not during the entire 60 minute trial [age 350	  
factor: F(1,128)=1.473, p=0.227]. Rearing, as measure of vertical activity (see Fig. 1D for 5 351	  
minute time bins), was similarly unaffected by the loss of xCT, as xCT-/- mice demonstrated 352	  
similar activity levels compared to their xCT+/+ littermates irrespective of age, for either the 353	  
first 5 minutes of the test [genotype factor: F(1,128)=1.318, p=0.253; Fig. 1E], or the entire 354	  
60 minute trial [genotype factor: F(1,128)=1.376, p=0.243; Fig. 1F]. The frequency of rearing 355	  
decreased with aging, independent of genotype, for both the first 5 minutes of the test [age 356	  
factor: F(1,128)=84.98, p<0.0001], as well as for the entire 60 minute trial [age factor: 357	  
F(1,128)=16.02, p=0.0001]. Altogether, the open field data reveal age-related decreases in 358	  
horizontal and vertical activity that occur in the absence of significant genotype effects, 359	  
indicating that loss of xCT does not affect spontaneous motor activity.  360	  
 361	  
In the rotarod test (Fig. 2A), xCT-/- mice performed equally as their xCT+/+ littermates, 362	  
irrespective of age [genotype factor: F(1,83)=0.615, p=0.435], demonstrating intact motor 363	  
coordination and balance. Concomitantly, we could notice an age-related decrease in motor 364	  
function independent of genotype [age factor: F(1,83)=17.08, p<0.0001]. In the nest building 365	  
test (Figs. 2B and C), xCT-/- mice performed equally well when compared to their xCT+/+ 366	  
littermates, irrespective of age, both when comparing the nest score [genotype factor: 367	  
F(1,62)=0.152, p=0.697], as well as the amount of nest building material shredded [genotype 368	  
factor: F(1,62)=0.169, p=0.682]. As with the rotarod and open field tests, we could notice 369	  
age-related decreases in motor function in the nest building test irrespective of genotype, both 370	  
when evaluating the nest score [age factor: F(1,62)=16.78, p=0.0001], as well as the amount 371	  
of nest building material shredded [age factor: F(1,62)=19.00, p<0.0001]. Finally, in the 372	  
adhesive removal test (Figs. 3A and B), xCT-/- mice demonstrated equal sensorimotor 373	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function compared to xCT+/+ littermates, both when evaluating time-to-contact [genotype 374	  
factor: F(1,54)=0.636, p=0.428] as well as time-to-remove [genotype factor: F(1,54)=0.190, 375	  
p=0.664].  376	  
 377	  
3.2. Effect of xCT deletion on visual acuity 378	  
To assess the effect of xCT deficiency and age on basic mouse visual function, we examined 379	  
the visual acuity of adult and aged xCT+/+ and xCT-/- littermates (Fig. 4) using the virtual-380	  
reality optomotor system established by Prusky and colleagues (Prusky et al., 2004). The 381	  
maximal spatial frequency that elicits optokinetic tracking or head movements to follow the 382	  
drifting gratings provides a proxy for mouse visual acuity in cycles per degree (c/d). Visual 383	  
acuity values (maximal spatial frequency; c/d) of the left and right eye were not different 384	  
within each group (adult xCT+/+ mice: p=0.706, t-test; adult xCT-/- mice: p=0.591, t-test; 385	  
aged xCT+/+ mice: p=0.704, t-test; aged xCT-/- mice: p=0.227, t-test) and were therefore 386	  
averaged for display. There was no significant genotype effect [genotype factor: 387	  
F(1,27)=0.125, p=0.726], and no significant interaction between age and genotype [age x 388	  
genotype factor: F(1,27)=0.026, p=0.872], hence no genotype-dependent effect on the visual 389	  
acuity was observed in either adult or aged mice. In contrast, a significant decline in acuity 390	  
was detected with aging in both genotypes [age factor: F(1,27)=34.84, p<0.0001]. This age-391	  
dependent decrease in spatial vision is consistent with previous findings in old C57BL/6-mice 392	  
(Lehmann et al., 2012). Together, the behavior effects observed in xCT-/- mice in this study 393	  
cannot be due to decreased or altered visual acuity since they show similar responses and age-394	  
dependency as xCT+/+ littermates in the optomotor test. 395	  
 396	  
3.3. Effect of xCT deletion on anxiety-like behavior 397	  
In the 60 minute open field test (Fig. 5C; see Fig. 5A for 5 minute time bins), xCT-/- mice 398	  
spent more time in the center of the arena compared to their xCT+/+ littermates [genotype 399	  
factor: F(1,128)=14.45, p=0.0002], an anxiolytic-like effect confirmed for adult (p=0.003) as 400	  
well as aged (p=0.017) mice. This effect was not observed, however, when evaluating the first 401	  
5 minutes of the test (Fig. 5B), during which xCT-/- mice spent a similar amount of time in 402	  
the center compared to their xCT+/+ littermates [genotype factor: F(1,128)=1.196, p=0.276]. 403	  
These findings indicate that, although the immediate reaction to the open field arena was 404	  
similar between genotypes, xCT-/- mice habituated quicker to the novel environment (Fig. 405	  
5A). In the light/dark paradigm (Figs. 5D and E), xCT-/- mice spent more time outside the 406	  
shelter compared to their xCT+/+ littermates [genotype factor: F(1,62)=4.835, p=0.031], an 407	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effect that seemed to be mainly due to a significant difference observed in adult mice 408	  
(p=0.013). On the other hand, no significant changes could be observed in the latency to exit 409	  
the shelter between the two genotypes [genotype factor: F(1,62)=2.627, p=0.110]. Also in the 410	  
light/dark paradigm, we could observe a global increase in anxiety-like behavior with aging 411	  
independent of genotype, that seemed to be observed both when evaluating time spent outside 412	  
the shelter [age factor: F(1,62)=14.60, p=0.0003] as well as the latency to exit the shelter [age 413	  
factor: F(1,62)=7.242, p=0.0091]. This age-dependent increase in anxiety-like behavior 414	  
confirms previous observations in rodents (Pietropaolo et al., 2014). In the novelty-suppressed 415	  
feeding test (Fig. 4F), we could also notice a global anxiolytic-like effect in the xCT-/- mice 416	  
independent of age [genotype factor: F(1,34)=4.395, p=0.043], as well as an increase in 417	  
anxiety-like behavior with age independent of genotype [age factor: F(1,34)=8.434, p=0.006]. 418	  
The decreased latency to feed in xCT-/- mice occurred in the absence of significant effects of 419	  
the xCT deletion on feeding behavior, as evaluated over 24 hours in the home cage or in a 420	  
metabolic cage (data not shown). Finally, in the elevated plus maze, no significant differences 421	  
could be observed either in time spent in the open arms [genotype factor: F(1,32)=1.478, 422	  
p=0.233; age factor: F(1,32)=0.919, p=0.345], or in the number of open arm entries [genotype 423	  
factor: F(1,32)=2.855, p=0.101; age factor: F(1,32)=1.505, p=0.229]. The mice included in 424	  
this study, however, demonstrated extreme low scores for elevated plus maze activity, 425	  
independent of genotype or age, despite our best efforts to use a standardized protocol. The 426	  
mean time spent in the open arms was 11.66 seconds out of a total trial time of 600 seconds 427	  
(approximately 2% of the total time), while the average number of total arm entries was 14.69 428	  
(average of 1.44 open arm entries and 13.64 closed arm entries; n = 36). Importantly, it has 429	  
been argued that low elevated plus maze activity could render the test unstable (Browne and 430	  
Lucki, 2013;  Crabbe et al., 1999;  Wahlsten et al., 2003). Furthermore, adult xCT-/- mice 431	  
demonstrate impairment in spatial working memory in the Y maze (De Bundel et al., 2011) 432	  
that might have influenced the alternation between closed and open arms of the maze. 433	  
Especially as the mice underperformed, we believe that interpretation of the elevated plus 434	  
maze data is not suited and will not be discussed further. 435	  
 436	  
3.4. Effect of xCT deletion on depressive-like behavior 437	  
Depressive-like behavior was evaluated in two behavioral despair paradigms, the forced swim 438	  
test and the tail suspension test. In the tail suspension test (Fig. 6A), xCT-/- mice spent less 439	  
time immobile compared to their xCT+/+ littermates [genotype factor: F(1,62)=25.14, 440	  
p<0.0001], an antidepressive-like effect visible for both adult (p=0.001) as well as aged 441	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(p=0.001) mice. In the forced swim test (Figs. 6B, C and D), loss of system xc- also lead to a 442	  
global decrease in immobility time [genotype factor: F(1,72)=9.420, p=0.003] that seemed to 443	  
be particularly due to an antidepressive-like effect observed in aged mice (p<0.0001). 444	  
Because of this particular difference, we could observe a global decrease in immobility time 445	  
with aging irrespective of genotype [age factor: F(1,72)=27.63, p<0.0001], as well as a 446	  
significant interaction effect [age x genotype factor: F(1,72)=11.25, p=0.0013]. The global 447	  
decrease in immobility in the xCT-/- mice seemed to be associated with an increase in 448	  
climbing but not swimming behavior [genotype factor: F(1,72)=6.286, p=0.0144], again 449	  
mainly due to a significant increase in climbing behavior in aged xCT-/- mice (p=0.005).  450	  
 451	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4. Discussion 476	  
Current theories for mood disorders focus mainly on biogenic amines and still all marketed 477	  
antidepressant drugs target monoamine reuptake transporters, monoamine oxidase and/or 478	  
monoamine receptors. Even though these drugs are the standard of treatment today, they have 479	  
significant limitations with regard to their slow onset of action and the substantial proportion 480	  
of refractory patients (Niciu et al., 2014;  Zarate et al., 2013). Glutamate, the major excitatory 481	  
neurotransmitter in the brain, has been linked with the pathogenic process occurring in 482	  
depression and anxiety disorders (for review see (Popoli et al., 2012;  Sanacora et al., 2008)). 483	  
Pre-clinical evidence indicates that modulation of glutamatergic signaling using metabotropic 484	  
glutamate receptor ligands (Swanson et al., 2005) or NMDA receptor antagonists (Pilc et al., 485	  
2013;  Sanacora et al., 2008) leads to anxiolytic and anti-depressive-like effects. 486	  
Administration of ketamine to rodents, for instance, was found to reduce immobility in the 487	  
forced swim and tail suspension tests, while also acting as anxiolytic in the novelty-488	  
suppressed feeding test and elevated plus maze (for review see (Browne and Lucki, 2013)). In 489	  
addition to effects on glutamate receptors, there has been recent interest on glutamate 490	  
metabolism and clearance as mechanisms in mood regulation. Glial astrocytes play an 491	  
important role in modulation of both actions. They control glutamatergic neurotransmission 492	  
by rapidly clearing synaptic glutamate thereby preventing spillover to the extrasynaptic space, 493	  
and also serve a central role in amino acid neurotransmitter metabolism by converting 494	  
glutamate into glutamine for the glutamate/glutamine cycle (Danbolt, 2001). Reduced brain 495	  
expression of excitatory amino acid transporters in depressed humans (Valentine et al., 2011) 496	  
as well as in a rat model for depression (Gomez-Galan et al., 2013) was in line with a rodent 497	  
study showing that enhanced glutamate uptake by ceftriaxone had antidepressant-like effects 498	  
(Mineur et al., 2007). 499	  
 500	  
System xc- is a plasma membrane transporter, believed to be located on glial cells, mediating 501	  
uptake of cystine and release of glutamate in a 1:1 ratio (Lewerenz et al., 2013). Cystine 502	  
imported by system xc- is converted to cysteine that can either participate in the synthesis of 503	  
glutathione, or be exported back to the extracelluar space via system ASC, and as such 504	  
regulate the extracellular cystine/cysteine redox couple (Lewerenz et al., 2013). In turn, 505	  
nonvesicular glutamate release via system xc- has been indicated in various regions of the 506	  
brain (Baker et al., 2003;  Baker et al., 2002;  De Bundel et al., 2011;  Massie et al., 2011). 507	  
Although system xc- participates in the modulation of glutamatergic signaling (Bridges et al., 508	  
2012), its role in behavioral regulation is poorly understood.  509	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 510	  
The precise distribution of system xc- in the brain has been difficult to evaluate, due to the 511	  
paucity of specific antibodies recognizing xCT (the specific subunit of system xc-) 512	  
appropriate for immunohistochemistry. Nevertheless, previous in situ hydbridization studies 513	  
indicated robust xCT expression in regions facing the cerebral ventricles as well as in 514	  
meninges, linking system xc- with maintenance of the redox state of the cerebrospinal fluid 515	  
(Sato et al., 2002). Furthermore, strong xCT expression was observed in the area postrema, 516	  
the medial habenular nucleus as well as the paraventricular thalamic nuclei (Sato et al., 2002). 517	  
Expression of system xc- in such discrete areas of the brain is intriguing, as it could be linked 518	  
with particular roles in the brain. Interestingly, lesions of the area postrema have been 519	  
previously found to decrease anxiety like behavior in rats (Miller et al., 2002). Furthermore, 520	  
the medial habenula has been linked with mediating anxiety and fear responses, while 521	  
increased activity has been linked with depression (Viswanath et al., 2013). Finally, the 522	  
paraventricular thalamic nuclei were recently shown to be activated in depressive-like states 523	  
(Zhu et al., 2011). Altogether, the strong expression of xCT in discrete regions mediating 524	  
stress, anxiety and depressive-like responses could indicate that this antiporter might be 525	  
relevant for the manifestation of such behaviors in vivo (Crawley and Paylor, 1997). 526	  
Furthermore, expression of system xc- is also present in other areas of the brain including the 527	  
hippocampus (De Bundel et al., 2011), striatum (Baker et al., 2002;  Massie et al., 2011), 528	  
nucleus accumbens (Baker et al., 2003), as well as in the cortex and cerebellum (Burdo et al., 529	  
2006;  Sato et al., 2002;  Shih et al., 2006), while recently Lutgen et al. described the presence 530	  
of xCT mRNA in the basolateral amygdala and bed nucleus of the stria terminalis (Lutgen et 531	  
al., 2014). In the current phenotypic study we embarked on the characterization of system xc- 532	  
deficient mice using a battery of tests assaying anxiety and depressive-like behavior, with the 533	  
hope of gaining further insight on the role of nonvesicular glutamate released by system xc- 534	  
on behavior.  535	  
 536	  
Due to the presence of system xc- in areas mediating sensorimotor control such as the basal 537	  
ganglia (Patel et al., 2014) or cerebellum (Proville et al., 2014), we first carefully evaluated 538	  
the potential impact of xCT deletion on sensorimotor function. In order to do so, we evaluated 539	  
different aspects of motor performance, ranging from motor coordination and balance 540	  
(rotarod), spontaneous behavior and exploration (open field) to fine movement skills and 541	  
correct sensorimotor integration (nest building and adhesive removal). Our results 542	  
consistently indicate that loss of xCT has no significant effect on motor and sensorimotor 543	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function, while observing age-related genotype-independent decreases in motor function in 544	  
the open field, rotarod and nest building tests. Our findings are in agreement with a recent 545	  
behavioral characterization of xCT-/- mice that similarly did not observe changes in motor 546	  
coordination or motor learning in the rotarod task, or in spontaneous motor activity in the 547	  
open field test (McCullagh and Featherstone, 2014). 548	  
 549	  
System xc- has also been found to be present and potentially functionally relevant in the eye. 550	  
Expression of system xc- has been described in the retina (Bridges et al., 2001;  Hu et al., 551	  
2008;  Kato et al., 1993), lens (Lim et al., 2005) and cornea (Langford et al., 2010), where it 552	  
might act to protect against oxidative stress. Indeed, various oxidative stress stimuli such as 553	  
xanthine/xanthine oxidase or hydrogen peroxide leads to increased xCT expression (Dun et 554	  
al., 2006;  Mysona et al., 2009), while intravitreal injection of system xc- inhibitor DL-α-555	  
aminoadipate leads to a decline in retinal GSH levels and retinal dysfunction (Kato et al., 556	  
1993). At the same time, increased glutamate release via an overactive system xc- might be 557	  
detrimental to retinal neurons, due to excitotoxic damage (Lewerenz et al., 2013;  Lim and 558	  
Donaldson, 2011). Conclusive studies on the functional involvement of system xc- in the eye 559	  
are lacking, and it is currently unclear whether system xc- contributes to visual function in 560	  
vivo. In the present study, we evaluated the basic visual acuity of system xc- deficient mice 561	  
using the optomotor test. Although we observed an age-related decline of visual acuity, in line 562	  
with previous observations in aged C57BL/6 mice (Lehmann et al., 2012), we did not detect 563	  
any significant differences between genotypes, in either adult or aged mice. Our data, thus, 564	  
suggest that system xc- might not play a major role in the subcortical-mediated visual acuity 565	  
in physiological conditions. At the same time, the age-related decline in visual acuity might 566	  
have contributed, at least partly, to the age-related effects observed in other behavioral tests 567	  
evaluating motor function or anxiety-like behavior. Further studies evaluating ocular GSH 568	  
and extracellular glutamate levels in xCT-/- mice, as well as the response of system xc- 569	  
deficient mice in animal models of visual deprivation, would be extremely important in 570	  
further defining the role of system xc- in visual function. 571	  
 572	  
The absence of significant effects on motor function or visual acuity in system xc- deficient 573	  
mice in each age group provided important controls to evaluate these mice in assays for 574	  
anxiety- and depressive-like behavior. In order to evaluate anxiety-like behavior, we tested 575	  
xCT-/- mice and their xCT+/+ littermates in various approach-avoidance paradigms. These 576	  
tests are based on the conflict between the innate exploratory behavior of rodents and their 577	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aversion towards open, bright, or elevated spaces, at risk for predation (Griebel and Holmes, 578	  
2013). In the 60 minute open field test, we could notice that system xc- deficient mice showed 579	  
decreased avoidance of the center area in both age groups, indicating an age-independent 580	  
anxiolytic effect of xCT deletion. This effect, however, could not be observed during the 581	  
initial 5 minutes of the trial, in line with previous findings evaluating xCT-/- mice during 582	  
short open field trials (De Bundel et al., 2011;  McCullagh and Featherstone, 2014). It is 583	  
believed that the initial stages of the open field test reflect the immediate reaction to the 584	  
mildly stressful novel environment, while long term observation periods reflect habituation 585	  
effects (Fonio et al., 2012). Our data, therefore, suggest that although xCT-/- mice show a 586	  
similar reaction upon the introduction to the open field arena, they habituate faster to this 587	  
novel environment compared to xCT+/+ littermates. In the light-dark paradigm, adult xCT-/- 588	  
mice spent significantly more time outside the shelter compared to their xCT+/+ littermates, 589	  
further reinforcing an anxiolytic behavior. Interestingly, this anxiolytic effect could not be 590	  
observed in aged xCT-/- mice, indicating an age-dependent effect. In the novelty-suppressed 591	  
feeding test, loss of system xc- globally decreased the latency to feed, also indicating a trend 592	  
for decreased anxiety-like behavior. In conclusion, our findings indicate an anxiolytic effect 593	  
of loss of system xc- in mice, observed in diverse paradigms tapping into distinct or 594	  
overlapping domains of anxious behavior (Ramos, 2008;  Turri et al., 2001).  595	  
 596	  
Next, we evaluated the effect of loss of system xc- on depressive-like behavior using two 597	  
behavioral despair tests. In these paradigms, mice are faced with an inescapable situation, 598	  
with their total test immobility time indicating reluctance to maintain an active escape-599	  
oriented behavior. An increase in immobility time is considered to indicate depressive-like 600	  
behavior (Cryan and Holmes, 2005). In the mouse tail suspension test, we could observe that 601	  
xCT-/- mice consistently demonstrated decreased immobility time compared to xCT+/+ 602	  
littermates, highlighting an age-independent antidepressive-like effect. In the forced swim 603	  
test, we could notice that aged, but not adult, xCT-/- mice had decreased immobility time, 604	  
with a concomitant increase in climbing but not swimming behavior. Importantly, aged xCT-605	  
/- mice did not demonstrate differences in performing complex and challenging motor tasks, 606	  
such as the rotarod task, and as such changes observed in the forced swim test are most likely 607	  
attributed to changes in mood, and not to a shift in motor phenotype. The finding that adult 608	  
xCT-/- mice demonstrate an antidepressant effect in the tail suspension test, but not in the 609	  
forced swim test, is intriguing, and might indicate different neurobiological pathways 610	  
mediating the response in the two tests. Indeed, in spite of the similarity at face value, the 611	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neurochemical pathways mediating behavior in the two paradigms are not believed to be the 612	  
same (Bai et al., 2001). This finding reinforces the antidepressive-like phenotype observed 613	  
after loss of system xc-, especially in the aged mice.  614	  
 615	  
Although assigning specific mouse tests to various human mood symptoms is understandably 616	  
difficult (Ramos, 2008), attempts have been made to model various manifestations of 617	  
depression in mice (Cryan and Holmes, 2005). In particular, immobility in behavioral despair 618	  
paradigms could be related to depressed mood, inappropriate reaction to a stressful situation, 619	  
helplessness, as well as psychomotor retardation (Cryan and Holmes, 2005). The latency to 620	  
feed in the novelty suppressed feeding, besides indicating anxiety, might also be related to 621	  
hedonic processes (Dulawa et al., 2004). Similarly, the quality of the nest built during the nest 622	  
building test, besides reflecting motor activity, could also be related to fatigue or loss of 623	  
energy as seen in major depression (Cryan and Holmes, 2005). Overall, our findings indicate 624	  
an antidepressive-like effect of xCT deletion, particularly regarding measures of behavioral 625	  
despair. The slightly decreased latency to feed in the novelty suppressed feeding test in 626	  
system xc- deficient mice indicates a potential implication in anhedonia, and merits further 627	  
investigation in more specific tests, such as the intracranial self-stimulation paradigm (Cryan 628	  
and Holmes, 2005).  629	  
 630	  
Geriatric depression is considered to entail a unique set of neurochemical and pathological 631	  
changes that distinguishes it from middle aged depression (Smith et al., 2007). As a 632	  
consequence, geriatric depression faces a greater variability in antidepressant treatment 633	  
response, an increased relapse rate, and a significant number of treatment resistant patients, as 634	  
well as an important impact of co-morbid anxiety on treatment response (Flint, 2005;  Smith 635	  
et al., 2007). Furthermore, minor depression is more frequent in older adults, and is more 636	  
likely to present with co-morbid anxiety (Byrne and Pachana, 2010). Interestingly, Slotkin et 637	  
al. indicate distinct effects of olfactory bulbectomy in aged versus young rats, both on 638	  
behavior, as well as on the serotonergic and catecholaminergic systems, and such 639	  
particularities in geriatric depression should be taken into account for antidepressant treatment 640	  
(Slotkin et al., 1999). In our phenotyping study, we observed age-related interactions between 641	  
loss of system xc- and both anxiety and depressive-like behavior, further reinforcing the idea 642	  
of a differential involvement of neurotransmitter systems, such as the glutamatergic system, 643	  
during late life. This finding is consistent with a recent behavioral evaluation of mGlu5-/- 644	  
mice, which showed differential effects of the mutation on anxiety and depressive-like 645	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behavior with age (Inta et al., 2013). In particular, due to a strong antidepressive-like effect 646	  
observed in the aged xCT-/- mice, we believe that system xc- could be an interesting target for 647	  
treatment of geriatric depression, especially when co-morbid with anxiety. Furthermore, as 648	  
loss of system xc- protects against nigrostriatal dopaminergic neurodegeneration (Massie et 649	  
al., 2011), this strategy could be of interest in treating age-related neurodegenerative disorders 650	  
such as Parkinson’s disease that have important co-occurrence of anxiety and depression 651	  
(Chaudhuri and Schapira, 2009). Finally, changes in affective behavior in aged system xc- 652	  
deficient mice occur in absence of impairment in either spatial reference memory or working 653	  
memory (De Bundel et al., 2011), which might favor such interventions in late-life psychiatric 654	  
disorders that are strongly associated with dementia and cognitive impairment (Laks and 655	  
Engelhardt, 2010;  Smith et al., 2007). 656	  
 657	  
Astrocytic glutamate release via system xc- can activate extrasynaptic NMDA receptors, as 658	  
well as group I and group II metabotropic glutamate receptors (Bridges et al., 2012). As 659	  
discussed above, antagonists for NMDA, as well as for some metabotropic glutamate 660	  
receptors can induce antidepressive- and/or anxiolytic-like effects (Pilc et al., 2013;  Sanacora 661	  
et al., 2008;  Swanson et al., 2005). Furthermore, overactivation of extrasynaptic NMDA 662	  
receptors can induce excitotoxicity (McCullagh and Featherstone, 2014) and might be 663	  
involved in the cellular and morphological changes observed in the prefrontal cortex or 664	  
hippocampus of patients with mood disorders (Popoli et al., 2012). Loss of system xc- has 665	  
been shown to be neuroprotective, possibly by reducing the extracellular glutamate levels and 666	  
the potential for excitotoxicity (Massie et al., 2011). Although highly speculative, the 667	  
observed behavioral changes in xCT-/- mice might be linked with a decreased activation of 668	  
extrasynaptic NMDA receptors, and/or reduced tonic stimulation of metabotropic glutamate 669	  
receptors, such as group II metabotropic glutamate receptors (Baker et al., 2002;  Moran et al., 670	  
2005). Further studies are warranted investigating the molecular mechanisms underlying the 671	  
anxiolytic and antidepressive-like behavior observed in xCT-/- mice. Still, by modulating 672	  
rather than strongly interfering with glutamatergic neurotransmission, inhibition of system xc- 673	  
might represent a safe approach in targeting glutamatergic dysfunction, especially when 674	  
associated with chronic disorders such as mood disorders (Bergink et al., 2004;  Pilc et al., 675	  
2013). 676	  
 677	  
Although our current findings indicate that system xc- mediates aspects of anxiety and 678	  
depressive-like behavior, certain limitations should be acknowledged. First, the retrospective 679	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nature of our study reflects a more heterogeneous experimental design, with different tests 680	  
performed for different batches of mice. Test history has been found to influence the results of 681	  
behavioral testing (Voikar et al., 2004). However, by ensuring that all individual batches were 682	  
matched by genotype and age, we believe that the potential bias of reporting genotype effects 683	  
due to test history is small. On the other hand, the retrospective nature of our study allowed 684	  
for a large sample size (which is sometimes limiting in behavioral research, see (Button et al., 685	  
2013)) and the evaluation of the xCT -/- mice in a large variety of paradigms that is 686	  
sometimes difficult to perform in a prospective study. Furthermore, employing different 687	  
batches of mice might also decrease the chance of reporting batch-related effects on behavior. 688	  
A second limitation of our study relates to the exclusive characterization of male system xc- 689	  
deficient mice. While our findings provide a starting point regarding the effects of system xc- 690	  
on behavior, it would be of interest to perform a similar phenotyping study on female mice, in 691	  
order to see if the effects of system xc- would be consistent across genders. Such studies 692	  
would be especially insightful, in light of the known differences that exist between genders 693	  
regarding regulation of mood and stress responses and the increased incidence of depression 694	  
and anxiety disorders in women (Young and Korszun, 2010).  695	  
 696	  
In a very recent report, Lutgen et al. indicate that system xc- inhibitor sulfasalazine leads to 697	  
increased anxiety-like behavior in rats in the open field and elevated plus maze tests, without 698	  
affecting depressive-like behavior in the forced swim test (Lutgen et al., 2014). These 699	  
findings are in contrast with our current observations, and widen the perspective and 700	  
complexity of behavioral modulation by system xc-. It is conceivable that these contrasting 701	  
results are due to different levels of system xc- inhibition (acute and partial with sulfasalazine, 702	  
versus chronic and complete in xCT-/- mice), or the species of animals used. At the same 703	  
time, however, sulfasalazine is known to have poor blood-brain barrier permeability in intact 704	  
animals (Liu et al., 2012), and peripheral and central off-target effects, such as anti-705	  
inflammatory properties (inhibition of nuclear factor kappa B, see (Wahl et al., 1998)) and 706	  
blockade of NMDA receptors (Ryu et al., 2003), that could influence acute effects on 707	  
behavior. Future studies will be of particular importance evaluating acute versus chronic 708	  
modulation of system xc- and its relation to emotional behavior. 709	  
 710	  
5. Conclusion 711	  
Our present findings indicate that system xc- mediates aspects of anxiety and depressive-like 712	  
behavior in mice. Inhibition of system xc-, in particular, might be an interesting and novel 713	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approach in the management of mood disorders, including those with late life onset. Further 714	  
studies are eagerly awaited evaluating this hypothesis in animal models of anxiety and 715	  
depression, and using selective pharmacological inhibitors of system xc- or conditional xCT 716	  
mutants. 717	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Figure Legends 938	  
 939	  
Fig. 1. Spontaneous motor behavior. Loss of system xc- does not affect horizontal (C) or 940	  
vertical (F) spontaneous motor activity as assessed in a 60 minute open field test (see A and D 941	  
for corresponding 5 minute time bins). Activity levels were similarly unaffected in xCT-/- 942	  
mice during the first 5 minutes of the trial (B, E). Data are presented as mean ± SEM *** 943	  
p<0.001 (2-way ANOVA), sample size indicated in figure. 944	  
 945	  
Fig. 2. Motor coordination and fine motor skills. Loss of system xc- does not affect motor 946	  
coordination and balance as assessed using an accelerating rotarod protocol (A), nor does it 947	  
influence fine motor skills and the capacity to build a nest (B, C). Data are presented as mean 948	  
± SEM *** p<0.001 (2-way ANOVA), sample size indicated in figure.  949	  
 950	  
Fig. 3. Sensorimotor behavior.  Loss of system xc- does not affect sensorimotor function as 951	  
evaluated in the adhesive removal test; xCT-/- mice demonstrate intact sensory function 952	  
(time-to-contact, A), as well as intact fine motor skills (time-to-remove, B). Data are 953	  
presented as mean ± SEM, sample size indicated in figure. 954	  
 955	  
Fig. 4. Visual acuity thresholds. Loss of system xc- does not affect spatial frequency 956	  
thresholds or visual acuity in either adult or aged mice tested in the optomotor setup. Data are 957	  
presented as mean ± SEM *** p<0.001 (2-way ANOVA), sample size indicated in figure. 958	  
 959	  
Fig. 5. Anxiety-like behavior. Loss of system xc- leads to age-independent anxiolytic effects 960	  
in the 60 minute open field test (C), that are not observed however in the first 5 minutes of the 961	  
trial (B), and potentially associated with facilitated habituation to the open field arena (A). 962	  
Loss of system xc- leads to age-dependent anxiolytic effects in the light/dark paradigm (D, E), 963	  
and global anxiolytic effects in the novelty suppressed feeding test (F). Data are presented as 964	  
mean ± SEM *** p<0.001, ** p<0.01, * p<0.05 (2-way ANOVA), ## p<0.01, # p<0.05 965	  
(Bonferroni post-hoc versus age-matched xCT+/+), sample size indicated in figure.  966	  
 967	  
Fig. 6. Depressive-like behavior. Loss of system xc- leads to age-independent antidepressive 968	  
effects in the tail suspension test (A), and age-dependent antidepressive effects in the forced 969	  
swim test (B), with increased climbing (D) but not swimming (C) behavior. Data are 970	  
presented as mean ± SEM *** p<0.001, ** p<0.01, * p<0.05 (2-way ANOVA), ### p<0.001, 971	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## p<0.01, # p<0.05 (Bonferroni post-hoc versus age-matched xCT+/+), sample size indicated 972	  
in figure.  973	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